An Allosteric Anti-tryptase Antibody for the Treatment of Mast Cell-Mediated Severe Asthma
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Summary Severe asthma patients with low type 2 inflammation derive less clinical benefit from therapies targeting type 2 cytokines, and represent an unmet need. We show that mast cell tryptase is elevated in severe asthma patients independent of type 2 biomarker status. Active β-tryptase allele count correlates with blood tryptase levels, and asthma patients carrying more active alleles benefit less from anti-IgE treatment. We generated a noncompetitive inhibitory antibody against human β-tryptase, which dissociates active tetramers into inactive monomers. A 2.15 Å crystal structure of a β-tryptase/antibody complex coupled with biochemical studies reveals the molecular basis for allosteric destabilization of small and large interfaces required for tetramerization. This anti-tryptase antibody potently blocks tryptase enzymatic activity in a humanized mouse model, reducing IgE-mediated systemic anaphylaxis and inhibits airway tryptase in Ascaris-sensitized cynomolgus monkeys with favorable pharmacokinetics. These data provide a foundation for developing anti-tryptase as a clinical therapy for severe asthma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
IgE and mast cells in allergic disease
Galli, S. J., & Tsai, M. (2012) · Nature Medicine · doi:10.1038/nm.2755 · Cited by 1,799 · cited 1×
“Approximately half of asthma patients exhibit elevated markers of type 2 cytokine-driven inflammation, including blood/sputum eosinophils, fractional exhaled nitric oxide (FeNO), serum periostin, and IgE, despite similar clinical presentation to “type 2-low” patients (Fahy, 2015; Galli and Tsai, 2012; Staton et al., 2…”
Shape Complementarity at Protein/Protein Interfaces
Lawrence, M. C., & Colman, P. M. (1993) · Journal of Molecular Biology · doi:10.1006/jmbi.1993.1648 · Cited by 1,331
Tryptase from human pulmonary mast cells. Purification and characterization
Schwartz, L. B., Lewis, R. A., & Austen, K. F. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)68496-6 · Cited by 419
Self-citationLyons, J. J., Yu, X., Hughes, J. D., Le, Q. T., Jamil, A., Bai, Y., Ho, N., Zhao, M., Liu, Y., O'Connell, M. P., et al. (2016) · Nature Genetics · doi:10.1038/ng.3696 · Cited by 394 · cited 7×
“With an increased understanding of tryptase genetics (Lyons et al., 2016; Trivedi et al., 2009), future studies with larger cohorts across diverse genetic backgrounds are needed to assess how active tryptase allele counts, α/β tryptase ratio, and α-tryptase copy number variation may contribute to asthma pathogenesis;…”
InfluentialSelf-citationMast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts
Cairns, J. A., & Walls, A. F. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119290 · Cited by 318 · cited 2×
“Tryptase has broad biological activities, including promoting proliferation and contraction of lung smooth muscle cells (SMC), stimulating collagen production by lung fibroblasts and degrading muscle relaxing neuropeptides (Berger et al., 2001; Cairns and Walls, 1997; Franconi et al., 1989; Hallgren and Pejler, 2006;…”
Characterization of genes encoding known and novel human mast cell tryptases on chromosome 16p13.3
Pallaoro, M., Fejzo, M. S., Shayesteh, L., Blount, J. L., & Caughey, G. H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.6.3355 · Cited by 146 · cited 1×
“TPSAB1 and TPSB2 are polymorphic and can generate 4 different isoforms: α-, βI-, βII-, and βIII-tryptase (depicted in Figure 2A) (Pallaoro et al., 1999) with α-tryptase being catalytically inactive (Huang et al.”
Le, Q. T., Lyons, J. J., Naranjo, A. N., Olivera, A., Lazarus, R. A., Metcalfe, D. D., Milner, J. D., & Schwartz, L. B. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20190701 · Cited by 126
Expression of α-tryptase and β-tryptase by human basophils
Jogie-Brahim, S., Min, H.-K., Fukuoka, Y., Xia, H.-Z., & Schwartz, L. B. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.02.032 · Cited by 113
Self-citationFukuoka, Y., & Schwartz, L. B. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.5.3165 · Cited by 35 · cited 2×
“Similar tetramer dissociation phenomena have been described for a previously described nonhuman anti-tryptase antibody and lactoferrin (Fukuoka and Schwartz, 2006; Hallgren et al., 2001).”
Self-citationLyons, J. J., Stotz, S. C., Chovanec, J., Liu, Y., Lewis, K. L., Nelson, C., DiMaggio, T., Jones, N., Stone, K. D., Sung, H., et al. (2018) · Genetics in Medicine · doi:10.1038/gim.2017.136 · Cited by 30 · cited 1×
“We also used whole genome next-generation sequencing (WGS) methods (Lyons et al., 2018; Lyons et al., 2016); results between Sanger sequencing and WGS are in accord (Figure S2A–C).”
Cited by
Miller, R. L., Grayson, M. H., & Strothman, K. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.10.001 · Cited by 365
Lyons, J. J., Chovanec, J., O’Connell, M. P., Liu, Y., Šelb, J., Zanotti, R., Bai, Y., Kim, J., Le, Q. T., DiMaggio, T., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.06.035 · Cited by 230
Self-citationAdvances and recent developments in asthma in 2020
Cevhertas, L., Ogulur, I., Maurer, D. J., Burla, D., Ding, M., Jansen, K., Koch, J., Liu, C., Ma, S., Mitamura, Y., et al. (2020) · Allergy · doi:10.1111/all.14607 · Cited by 196
Greiner, G., Sprinzl, B., Górska, A., Ratzinger, F., Gurbisz, M., Witzeneder, N., Schmetterer, K. G., Gisslinger, B., Uyanik, G., Hadzijusufovic, E., et al. (2021) · Blood · doi:10.1182/blood.2020006157 · Cited by 189
Treatment options in type-2 low asthma
Hinks, T. S. C., Levine, S. J., & Brusselle, G. G. (2021) · European Respiratory Journal · doi:10.1183/13993003.00528-2020 · Cited by 187
“In support of this concept, administration of a stable LXA4 analogue inhibited allergic airway inflammation and AHR in an experimental murine model of OVA-induced airways disease[170], while inhalation of LXA4 by 5 mild asthmatics antagonized the bronchoconstrictive effects of leukotriene C4[171].”
BackgroundInfluential
Metadata
- Authors
- Maun, H. R., Jackman, J. K., Choy, D. F., Loyet, K. M., Staton, T. L., Jia, G., Dressen, A., Hackney, J. A., Bremer, M., Walters, B. T., Vij, R., Chen, X., Trivedi, N. N., Morando, A., Lipari, M. T., Franke, Y., Wu, X., Zhang, J., Liu, J., Wu, P., Chang, D., Orozco, L. D., Christensen, E., Wong, M., Corpuz, R., Hang, J. Q., Lutman, J., Sukumaran, S., Wu, Y., Ubhayakar, S., Liang, X., Schwartz, L. B., Babina, M., Woodruff, P. G., Fahy, J. V., Ahuja, R., Caughey, G. H., Kusi, A., Dennis, M. S., Eigenbrot, C., Kirchhofer, D., Austin, C. D., Wu, L. C., Koerber, J. T., Lee, W. P., Yaspan, B. L., Alatsis, K. R., Arron, J. R., Lazarus, R. A., & Yi, T.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 179
- Issue
- 2
- Pages
- 417-431.e19
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W2943823713
- Cited by
- 110
- References
- 11
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.